Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


RC(=O)N containing (i.e., carboxamide) (R is C or H)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514553000 - Radical -XH acid, or anhydride, acid halide or salt thereof (X is chalcogen) DOAI

514557000 - Carboxylic acid, percarboxylic acid, or salt thereof (e.g., peracetic acid, etc.)

514561000 - Nitrogen other than as nitro or nitroso nonionically bonded

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20130158122EP2 Agonist from Non-Prostanoid Structures Designed as PGE2 Antagonists - A method of treating ocular hypertension, lowering intraocular pressure, pain or inflammation, comprising administering to a mammal a pharmaceutical composition of an EP06-20-2013
20100113597PHARMACEUTICAL COMPOSITION FOR PREVENTION OF PROGRESS OF INTESTINAL CONSTRICTION ASSOCIATED WITH CROHN'S DISEASE - The present invention provides an oral pharmaceutical composition for inhibiting the progression of intestinal stricture associated with Crohn's disease. That is, the present invention relates to a pharmaceutical composition for inhibiting the progression of intestinal stricture associated with Crohn's disease which comprises as an active ingredient N-(3,4-dimethoxycinnamoyl)anthranilic acid (generic name: tranilast) or a pharmaceutically acceptable salt thereof. The present invention can provide a pharmaceutical composition useful as an agent for inhibiting the progression of intestinal stricture associated with Crohn's disease for medical therapy.05-06-2010
20130030053NOVEL NIDDM REGIMEN - The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone.01-31-2013
20130079412Branched 3-phenylpropionic acid derivatives and their use - The present application relates to novel 3-phenylpropionic acid derivatives which carry a branched or cyclic alkyl substituent in the 3-position, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.03-28-2013
20100041756 METHOD OF MODULATING B CELL FUNCTIONING - The present invention relates generally to a method of modulating cellular functioning. More particularly, the present invention relates to a method of modulating B cell functioning, for example B cell proliferation, utilising an IDO-mediated tryptophan metabolite as herein defined (particular examples of such IDO-mediated tryptophan metabolites include 3-hydroxykynurenic acid, 3-hydroxyanthranilic acid, picolinic acid, quinolinic acid and tranilast). The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate B cell functioning such as antibody production, autoimmune conditions and B cell proliferation and neoplasias. In a related aspect, the present invention is directed to a method of therapeutically and/or prophylactically treating rheumatoid arthritis via the administration of the above-mentioned compounds.02-18-2010
20090156680Deodorants Containing Aminoacid Derivatives - A deodorant composition comprising an aminoacid compound of formula I or II and a carrier material. I R06-18-2009
20090042987TREATMENT OF NEUROPATHIC PAIN - A method of decreasing neuropathic pain in a mammal, comprising administering to said mammal an effective amount of tranilast for a period of time sufficient to decrease pain.02-12-2009
20090306209ENTERIC-COATED FORMULATIONS OF POLYETHYLENE GLYCOL AND ONE OR MORE SOLUBLE AMINO ACIDS FOR ORAL INGESTION AND ENHANCED UPTAKE OF SAME - Oral amino acid formulations comprising polyethylene glycol are enteric coated. Most preferred amino acids are leucine, glutamine, and arginine. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight polyethylene glycols may range from 190 to 9000.12-10-2009
20090306208PROPHYLACTIC OR THERAPEUTIC COMPOSITION FOR HEMOGLOBINURIA OR MYOGLOBINURIA - A prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria which may occur in humans or animals upon loading of exercise or stress or the like is provided.12-10-2009
20130059914Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof - Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.03-07-2013
20090281186Composition and Method for Reducing Stress - The present invention relates to a composition and method for reducing stress, in a mammal, wherein said composition acts by modulating levels and activities of various neurotransmitters and enhancing the phosphotidyl-inositol second messenger system affected by neurotransmitters. The composition of the present invention comprises at least L-theanine, including derivatives of L-theanine, and inositol, including derivatives of inositol.11-12-2009
200902705054-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES - This invention relates to novel 4-dimethylaminobutyric acid derivatives of the formula10-29-2009
20090258946ELECTROSTATICALLY CHARGED NASAL APPLICATION MULTIPURPOSE PRODUCTS AND METHOD - A family of products designed to ameliorate sinusitis and allergic rhinitis, produced by combining certain chemical substances with existing products, thereby producing a synergistic effect and relief. The chemical substances create an electrostatically charged field around the nose and prevent allergens or pollutants from entering the nostrils to cause a reaction, illness, or discomfort for the user. Therefore, the Present Invention comprises products, which are applied to the face, and therefore around the nose and nasal passages, as well as those applied directly into the nose. These products include but are not limited to nasal sprays, rinses, washes, sunscreens, nasal strips, swabs (medicated and non-medicated), tissues, towelettes, cosmetics, and fragrances. Common nasal sprays often comprise saline solutions. Cosmetics comprise camouflage paint or theatrical makeup. The principle function of the Present Invention is to prevent harmful airborne particulates from entering the nose when either sprayed into the nose or applied to the face, nose, or nasal passages.10-15-2009
20090253796METHOD FOR TREATING VASCULAR DISEASE - A medicament for prophylactic and/or therapeutic treatment of a vascular disease such as vascular restenosis and/or reocclusion after percutaneous transluminal coronary angioplasty using an intravascular stent, which comprises as an active ingredient a substance selected from the group consisting of retinoids and agents for controlling actions of retinoids such as 4-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid or a salt thereof, or 4-[[[3,5-bis-(trimethylsilyl)phenyl]carbonyl]amino]benzoic acid or a salt thereof, wherein said substance has substantially no antiproliferative action on vascular endothelial cells, but substantially has antiproliferative action on vascular smooth muscle cells.10-08-2009
20090234011N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS - Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione.09-17-2009
20090234010MANUFACTURE PROCESS OF ORGANIC COMPOUNDS - The present invention relates to a method of preparing N-substituted salicylamides or derivatives thereof and their derivatives, e.g. their salts. In particular, the present invention relates to a method of preparing (N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC) and its corresponding disodium monohydrate.09-17-2009
20100087535EXTERNAL COMPOSITION FOR SKIN - A moisturizing agent comprising one or more than one compound selected from the group consisting of lysyl-β-alanine represented by the following general formula (1) and a salt thereof:04-08-2010
20120238628DIHYDRONAPHTHALENE AND NAPHTHALENE DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS - The present invention relates to novel dihydronaphthalene and naphthalene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.09-20-2012
20110028552MEXILETINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF - The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) with amino acids or peptides and pharmaceutical compositions containing such prodrugs. Methods for providing pain relief, treating arrhythmia, decreasing the adverse GI side effects associated with mexiletine, increasing the bioavailability of mexiletine, and improving the pharmacokinetic reproducibility of mexiletine with the aforementioned prodrugs are also provided. Oligopeptides incorporating lysine or arginine residues attached directly or indirectly through a glycine residue are also described herein.02-03-2011
20090018198METHOD FOR TREATING A MOTONEURON DISORDER - The present invention is directed to the use of a class of peptide compounds for treating amyotrophic lateral sclerosis (ALS) and other forms of motoneuron diseases and peripheral neuropathies.01-15-2009
20080207757Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same - Disclosed are polar, hydrophilic stimulant prodrug compositions comprising at least one stimulant chemically attached to a polar hydrophilic ligand, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed.08-28-2008
20110288173Use of neboglamine in the treatment of toxicodependency - Use of neboglamine, (S)-4-amino-N(4,4-dimethyl-cyclohexyl)glutamic acid (CR 2249) (CAS Registry Number 163000-63-3), the racemic mixture thereof or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the treatment of toxicodependency induced by drugs such as CNS sedatives such as opiates, barbiturates, benzodiazepines, alcohol, stimulants such as amphetamines and cocaine, and hallucinogens such as LSD, mescalin, cannabis (marijuana) or fencyclidine.11-24-2011
20120190747METHOD OF TREATMENT USING FATTY ACID SYNTHESIS INHIBITORS - The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat and prevent diseases such as obesity, cancer, diabetes, fungal infections, 07-26-2012
20100168238PHARMACEUTICAL COMPOSITION CONTAINING PHLOROGLUCINOL AND PARACETAMOL - The invention relates to a pharmaceutical composition for oral or rectal administration, that contains phloroglucinol and paracetamol in a pharmaceutically acceptable carrier. The inventors have evidenced a synergy developed by these two active ingredients in antispasmodic therapy.07-01-2010
20100004335ORAL PREPARATION FOR PREVENTING OR IMPROVING SKIN DRYNESS - An oral preparation for the prophylaxis or improvement of dry skin accompanied by atopic dermatitis, xeroderma, chapped hand, chapped skin and the like is provided. The present invention can provide an oral preparation for the prophylaxis or improvement of dry skin, which comprises citrulline or a salt thereof as an active ingredient.01-07-2010
20120190746AFLATOXIN PRODUCTION INHIBITOR AND METHOD FOR CONTROLLING AFLATOXIN CONTAMINATION USING THE SAME - The present invention relates to provide an aflatoxin production inhibitor that inhibits aflatoxin production specifically and efficiently, is highly safe, and is practical, and an efficient production method thereof; and a method for controlling aflatoxin contamination that uses the aflatoxin production inhibitor, specifically relating to an aflatoxin production inhibitor that includes at least one of a dioctatin represented by the following formula (I) and a derivative thereof, as an active ingredient:07-26-2012
20110172308Antagonsim of PGF2a Receptor to Treat Hyertension Characterized by Activation of the Renin-Angiotensin-Aldosterone System - The present invention relates to methods for identifying candidate therapeutics for hypertension. The invention further provides a method for treating hypertension and/or decreasing atherogenesis by administration of an inhibitor of PGF07-14-2011
20110034557ANTIMICROBIAL COMPOSITIONS AND USES THEREOF - Antimicrobial compositions and methods of using the compositions are described herein. The compositions include an antibacterial acyl amino acid. In some embodiments, the acyl amino acid is a fatty acylated glutamate. The methods herein include methods of using acyl amino acids for treating and preventing bacterial infections.02-10-2011
20090088475Indanone derivatives that inhibit prolyl hydroxylase - Compounds of Formula I are useful inhibitors of HIF prolyl hydroxylases. Compounds of Formula I have the following structure:04-02-2009
20090042988PHARMACEUTICAL COMPOSITIONS CONTAINING A MEGLITINIDE COMPOUND FOR PREVENTING HEPATIC FIBROSIS - The present invention discloses pharmaceutical compositions for preventing, improving or treating hepatic fibrosis, hepatocellular degeneration or cirrhosis, which contain a meglitinide compound such as nateglinide.02-12-2009
20100137442Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment - Sustained release particulate oral dosage forms of (R)-baclofen prodrugs and methods of treating a disease comprising orally administering such dosage forms are disclosed. 06-03-2010
20080280982Glucagon Receptor Antagonists, Preparation and Therapeutic Uses - The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.11-13-2008
20080287542Novel Isovaleramide Forms, Compositions Thereof, and Related Methods of Use - The invention provides novel isovaleramide forms. These forms include isovaleramide co-crystals, and solvates, hydrates, co-crystals, and polymorphs thereof. The invention also provides novel compositions comprising these novel forms and one or more suitable carriers. The invention also provides related methods of treatment or prevention. Compositions and methods of the invention have a number of uses, including the treatment or prevention of epilepsy and anxiety.11-20-2008
20080280983METHODS OF TREATING RETT SYNDROME - The present embodiments relate to methods for the treatment of Rett Syndrome. More specifically, the present embodiments relate to pivagabine for use in the treatment of Rett Syndrome. Some embodiments relate to treatment of a patient with Rett Syndrome. Other embodiments relate to treatment of the indications of Rett Syndrome.11-13-2008
20120142778MICROBIOLOGICAL METHOD FOR SYNTHESIZING CINNAMOYL AMIDE DERIVATIVES OF AMINO ACIDS - Method for the microbiological production of cinnamoyl amide derivatives of amino acids, certain products that result therefrom and uses thereof, especially as antioxidants.06-07-2012
20100144881CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND - The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline solid forms.06-10-2010
20090082450DEUTERIUM-ENRICHED DICLOFENAC - The present application describes deuterium-enriched diclofenac, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-26-2009
20090137672ABUSE-RESISTANT AMPHETAMINE PRODRUGS - The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.05-28-2009
20080319074Glucagon Receptor Antagonists, Preparation and Therapeutic Uses - The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.12-25-2008
20080319073COLONIC DELIVERY THERAPEUTIC AGENTS FOR INFLAMMATORY BOWEL DISEASE - The present invention discloses a therapeutic agent for inflammatory bowel disease, which is in the from of delivering 1 to 5 g of glutamine to the large intestine per one administration; and the therapeutic agent for inflammatory bowel disease with which an anti-inflammatory agent(s) is combined. This therapeutic agent for inflammatory bowel disease can safely and effectively treat inflammatory bowel disease including ulcerative colitis without increasing the frequency of bowel movements.12-25-2008
20090197959N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS - Described herein are compounds that are antagonists of PGD08-06-2009
20090197957Methods and compositions for the treatment of pain - The present invention relates generally to the area of pain management and more particularly, to a method of analgesia and agents useful for same. More particularly, the present invention relates to a method of analgesia utilising a compound of formula (I). The method of the present invention is useful, inter alia, in the therapeutic or prophylactic treatment of pain, including acute pain, chronic non-malignant pain and chronic malignant pain. Also provided are compounds for use in the method of the invention.08-06-2009
20090105343Cancer Therapy And Medicaments Therefor - The present invention relates to a novel cancer therapy, particularly, but not exclusively, to a prostate, bladder and breast cancer therapy and to Compositions and medicaments for use in said therapy. In one aspect there is provided a method of treating a patient afflicted with cancer comprising administering to the patient a therapeutically effective amount of a nuclear receptor ligand and an HDAC (histone deacetylases) inhibitor wherein said nuclear receptor ligand is not a ligand for the vitamin D receptor.04-23-2009
20090209648Phenylacetic Acid Derivatives - Compounds of formula (I) pharmaceutically acceptable salts thereof, and pharmaceutically acceptable esters thereof; which are useful for the treatment of COX-2 dependent disorders.08-20-2009
20100216886POLYMORPHS OF N2-(1,1'-BIPHENYL-4-YLCARBONYL)-N1-[2-(4-FLUOROPHENYL)-1,1-DIMETHYLETHYL]- -L-ALPHA-GLUTAMINE - Disclosed are novel polymorphic forms of N08-26-2010
20110118352OAT EXTRACTS: REFINING, COMPOSITIONS AND METHODS OF USE - A simple and efficient method for the production of stable, clear, high-potency oat extracts is disclosed. The method employs the use of differential dissociation constants and ultrafiltration to stabilise extracts, prevent hazing, and prevent the loss of functional activity as an anti-irritant and anti-oxidant. Also disclosed are compositions of oat extracts derived from whole oat grains and oatmeal. Further disclosed are compositions of oat extracts for use in cosmetic, nutraceutical, therapeutic medical and veterinary preparations.05-19-2011
20100298436EP2 Agonist from Non-Prostanoid Structures Designed as PGE2 Antagonists - An EP2-receptor agonist of the following structure is disclosed:11-25-2010
20100324140GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES - The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.12-23-2010
20100063150Aflatoxin Production Inhibitor and Method for Controlling Aflatoxin Contamination Using the Same - An object of the present invention is to provide an aflatoxin production inhibitor that inhibits aflatoxin production specifically and efficiently, is highly safe, and is practical, and an efficient production method thereof; and a method for controlling aflatoxin contamination that uses the aflatoxin production inhibitor.03-11-2010
20110251280Stable Aqueous Compositions Comprising Amide-Protected Bioactive Creatine Species and Uses Thereof - The present invention provides amide-protected creatine molecules and compositions, containing one or more bioactive forms of creatine in aqueous compositions, wherein bioactive forms of creatine do not appreciably degrade into creatinine. Also provided are various beneficial effects of administering aqueous compositions having at least one amide-protected creatine molecule.10-13-2011
20090312422METHOD OF MODULATING CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME - Described is a rational design of therapeutic and/or prophylactic methods of treating conditions characterized by aberrant or otherwise unwanted microglial cell functioning and rational design methods for treating a range of neurological disorders which are characterized by nitric oxide induced neuronal damage.12-17-2009
20100048708TAMIBAROTENE CAPSULE PREPARATION - The present invention provides a practical preparation form of Tamibarotene and dosage form thereof, which exhibit high absorptivity by the body with minimized toxicity, and which are safe and stable without any risk of contamination. It is provided a Tamibarotene capsule preparation which encapsulates a composition comprising an oil component as its base and Tamibarotene as an active ingredient dissolved in the base. It is preferred that the oil component be propylene glycol fatty acid esters or polyethylene glycols. It is also preferred that the Tamibarotene capsule preparation comprise 0.1-50 mg/mL of the Tamibarotene based on the oil component.02-25-2010
20090030080Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states - This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans,trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.01-29-2009
20090215900COMPOSITION AND METHOD FOR PROVIDING GLUTAMINE - A process for preparing a glutamine-supplemented food product by contacting water and a nutritive base that pre-dominantly comprises meat and carbohydrate with a peptide source of glutamine to form a wet mixture and heating the wet mixture at a temperature of from about 50° C. to about 105° C. for a time sufficient to cook the nutritive base. The process forms a cooked food composition comprising from about 60% to about 85% by weight water. The product is useful for feeding to an animal to increase glutamine absorption or to strengthen immune function.08-27-2009
20090215899N-Phenyloxamide derivatives - A compound represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof having an inhibitory action against plasminogen activator inhibitor-1 (PAI-1):08-27-2009
20100063151ACYLAMIDE COMPOUNDS HAVING SECRETAGOGUE OR INDUCER ACTIVITY OF ADIPONECTIN - The present invention provides acylamide compounds, prodrugs thereof, or pharmaceutically acceptable salts thereof; and an adiponectin inducer or secretagogue, and therapeutic methods by administering the same.03-11-2010
20110082209Novel Salts of (4--2-Methylphenyl)Carbonyl]Amino}-3-Methylphenyl)Acetic Acid - A series of novel salt forms of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.04-07-2011
20110251281Composite Material Comprising High-Molecular-Weight Matrix and Low-Molecular-Weight Organic Compound and Process For Producing Same - Previously reported composite materials comprising a hydrophilic high-molecular-weight matrix and a low-molecular-weight organic compound involve a problem in that: it is difficult to compound a high load of the low-molecular-weight organic compound in the high-molecular-weight matrix; and thus produced composite material yields a high-molecular-weight matrix component that can form a thrombus when contacting with blood. Now, it becomes possible to produce a composite material having an antithrombogenic activity and a high content of a low-molecular-weight organic compound by the present invention comprising the steps of: crosslinking a polymer with an organic acid derivative which is used as a crosslinker in an organic solvent while at the same time embedding the low-molecular-weight organic compound therein; and substituting the organic solvent by water after the production of the high-molecular-weight matrix to effect precipitation and compounding of the low-molecular-weight organic compound in the high-molecular-weight matrix.10-13-2011
20110160307Compositions and Methods for Treating Hemorrhagic Conditions - A method of treating a hemorrhagic condition in a subject in need thereof, comprising administering a composition comprising a therapeutically effective amount of Dencichine, a co-solvent, a dispersion supporter, and optionally a cryoprotectant. Compositions and formulations comprising a solid dispersion composition of Dencichine and methods for preparation of same are also described.06-30-2011
20120202881Novel NIDDM Regimen - The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone.08-09-2012
20090253795Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibiton of pain and inflammation - A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that demonstrates substantial agonist activity at alpha adrenergic receptors and that is selected for peripheral (local) vasoconstriction and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.10-08-2009
20120302641BIPHENYL DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS - The present invention is directed to biphenyl derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.11-29-2012
20100305207GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF - This invention relates to a novel compound which is a glycogen phosphorylase inhibitor and its use in the treatment of diabetes and other conditions associated therewith. The invention further relates to a pharmaceutical composition containing the compound and to processes for preparing the compound and pharmaceutical composition.12-02-2010
20100022650Benzamide Derivatives As EP4 Receptor Agonists - A compound of formula (I) or a pharmaceutically acceptable derivative thereof,01-28-2010
20100016435HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES - Novel chemical agents are described. More specifically, hybrid molecules comprising a vitamin D receptor agonist moiety and an HDAC inhibitor moiety are described herein.01-21-2010
20110065795(1S,2S,3S,4R)-3-[(1S)-1-ACETYLAMINO-2-ETHYL-BUTYL]-4-UANIDINO-2-HYDROXYL-C- YCLOPENTYL-1-CARBOXYLIC ACID HYDRATES PHARMACEUTICAL USES THEREOF - The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.03-17-2011
20080319075Polymorphic forms of nateglinide - Provides are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, O, P, Q, T, U, V, Y, α, β, γ, δ, ε, σ, θ and Ω, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration.12-25-2008
20090197958Sustained Release Particulate Oral Dosage Forms of (R) Baclofen and Methods of Treatment - Sustained release particulate oral dosage forms of (R)-baclofen prodrugs and methods of treating a disease comprising orally administering such dosage forms are disclosed.08-06-2009
20090247637Novel Anthranilic Acid Derivatives - The invention is concerned with novel anthranilic acid derivatives of formula (I)10-01-2009
20100227925SENSITIZING COMPOUND AND METHOD FOR INCREASING SEXUAL SENSITIVITY - A clitoral sensitizing agent includes a base, L-citrulline, and a promotional vehicle.09-09-2010
20110144205Blood Glutathione as a Biomarker for Screening Asymptomatic Patients at Risk for Heart Failure - The present invention relates to a method for screening an asymptomatic patient at risk for heart failure, said method comprising measuring the concentration of glutathione in a blood sample obtained from said patient.06-16-2011
20110112194Medicaments Containing Pantothenic Acid - This invention relates to medicaments and their use in the alleviation of inflammation and pain in joints.05-12-2011
20090286881SELECTED BETAINES AND THEIR USES - A physiologically acceptable, sterile and pyrogen-free solution of betaine dissolved in a physiologically acceptable solvent, having a pH adjusted to from 5.0 to 8.0 with a betaine concentration of from 5 to 500 mg/ml.11-19-2009
20090239950METHODS FOR SYNTHESIS OF PRODRUGS FROM 1-ACYL-ALKYL DERIVATIVES AND COMPOSITIONS THEREOF - The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require the use of activated intermediates and/or toxic compounds and is readily amendable to scale-up. The current invention also provides 1-acyl-alkyl derivatives of known drug components and methods for synthesizing these 1-acyl-alkyl derivatives.09-24-2009
20120115956USE OF ISOLEUCINE N-HEXADECANOYL AS A "VOLUMIZING" AND/OR "PLUMPING" AGENT FOR HUMAN SKIN - The invention relates to the cosmetic use of isoleucine N-hexadecanoyl of formula (I): CH05-10-2012
20120157535PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DYSMENORRHEA - Disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof. Specifically disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof, which comprises tranilast as an active ingredient thereof.06-21-2012
20090253794Fibroblast Activator, Collagen Production Promoter, Collagen Contraction Promoter, Hyaluronic Acid Production Promoter, ATP Production Promoter, Melanin Formation Inhibitor, and Agent for External Application to the Skin - The present invention is a fibroblast activator, collagen production promoter, collagen contraction promoter, hyaluronic acid production promoter, ATP production promoter or melanin formation suppressor, which contains, as an active ingredient, at least one kind of compound selected from the group consisting of conagenin, a conagenin derivative, and a pharmaceutically acceptable salt thereof, as well as a composition (skin external preparation, cosmetic, pharmaceutical product or food, which is a composition for the improvement of wrinkles or a whitening composition) containing such activator, promoter or melanin formation suppressor.10-08-2009
20110065797DELOXIGLUMIDE AND PROTON PUMP INHIBITORS COMBINATION IN THE TREATMENT OF GASTROINTESTINAL DISORDERS - Cholecystokinin-1 (CCK1) receptor antagonists and the combination of CCK1 receptor antagonists and proton pump inhibitors (PPI) for the treatment of patients suffering from gastrointestinal or related disorders that have failed to completely respond to conventional acid suppression therapy.03-17-2011
20110065796PRODRUGS OF GUANFACINE - Prodrugs of guanfacine with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with guanfacine prodrugs are provided herein. Additionally, methods for minimizing or avoiding the adverse gastrointestinal side effects associated with guanfacine administration, as well as improving the pharmacokinetics of guanfacine are provided herein.03-17-2011
20100093863USE OF CITRULLINE FOR PREVENTING AN INCREASE IN PROTEIN CARBONYLATION AND FOR TREATING DISEASES RESULTING THEREFROM - A method of using L-citrulline of the formula (I) for preparing a cosmetic composition, a food or nutraceutic composition or a pharmaceutical composition for treating diseases related to an increase in protein carbonylation, in particular for treating neurodegenerative diseases such as Alzheimer's or Parkinson's disease.04-15-2010
20120172448Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof - The present application relates to novel substituted 1-benzylcycloalkylcarboxylic acid derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.07-05-2012
20090143469SALTS OF NATEGLINIDE - The present invention relates to salts of organic acid, in particular salt of nateglinide, combined preparations comprising one or more salts of nateglinide and, optionally, one or more additional ingredients and the use thereof in pharmaceutical compositions for preventing or treating diabetes, cardiovascular disease, or conditions associated therewith.06-04-2009
20100029767ANTHRANILIC ACID DERIVATIVES - Compounds of formula (I) are provided, wherein X is CH═CH, CH02-04-2010
20090018197METHODS FOR TREATING STATUS EPILEPTICUS AND RELATED CONDITIONS - The present invention is directed to the novel use of a class of peptide compounds for treating status epilepticus or related conditions, e.g. acute repetitive seizures, seizure clusters, etc.01-15-2009
20120264826N-Acetyl Beta Alanine Methods of Use - Methods for increasing athletic performance, preventing paresthesia, increasing beta alanine absorption and cell membrane permeability through both passive diffusion and active transport, and increasing the half-life of beta alanine present in a blood stream in a human or animal are disclosed. Each method includes administering to the human or animal a pharmaceutically effective amount of N-Acetyl Beta Alanine or an N-Acetyl Beta Alanine composition.10-18-2012
20080300308Glucagon Receptor Antagonists, Preparation and Therapeutic Uses - The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.12-04-2008
20110039933S1P-1 RECEPTOR AGONISTS - The invention provides compounds formula (I), their preparation, and their use as pharmaceutically active immuno-suppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SIP receptors.02-17-2011
20110237673Novel NIDDM Regimen - The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone.09-29-2011
20120101163COMPOSITION FOR INHIBITING CANCER METASTASIS - The invention provides a composition for inhibiting cancer metastasis, including: an effective amount of an amino acid hydroxamic acid derivative having a formula as shown as formula (I), formula (II) or formula (III):04-26-2012
20080249175N-Phenyloxamide derivatives - A compound represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof having an inhibitory action against plasminogen activator inhibitor-1 (PAI-1):10-09-2008
20080227861Inhibition of Allergic Contact Dermatitis By N-L-ALPHA-ASPARTYL-L-PHENYLALANINE 1-METHYL ESTER - It has now been found that N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM) and/or one of its lower alkyl derivatives can be used to treat allergic contact dermatitis associated with irritating oils such as catechol-containing plant-derived antigens such as poison ivy, poison oak, poison sumac and Asian lacquer tree and oils containing capsaicin. Topical application of APM and/or derivative can reduce or alleviate the symptoms associated with irritation of the skin and/or mucous membranes caused by contact or inhalation of these oils or fumes from burning vegetation containing these oils.09-18-2008
20130178531Methods and compositions for the treatment of diverticulosis - The present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis. In a method aspect, the present invention provides a method of treating diverticulosis. The method includes ingestion of 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diverticulosis.07-11-2013
20130143968Methods and compositions for the treatment of diabetes and related symtoms - The present invention is directed to methods and compositions for the treatment of diabetes and related symptoms. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diabetes and related symptoms. In a method aspect, the present invention provides a method of treating diabetes. The method involves ingesting 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diabetes.06-06-2013
20100286274Methods of Diagnosing, Monitoring and Treating Pulmonary Diseases - The invention includes methods of discriminating asthma from obstructive pulmonary disease, of treating pulmonary diseases, of treating cough, of assessing the efficacy of a treatment for an obstructive pulmonary disease, and of inhibiting activation of a P2-purinoreceptor (P2R).11-11-2010
20110275716COMPOSITION AND METHOD FOR TREATMENT OF DIABETES - The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of butyric acid, bile acid, long chain fatty acid, or glutamine to the colon by bypassing the upper digestive tract.11-10-2011
20130150447NOVEL OIL-IN-WATER COSMETIC EMULSIONS INCLUDING N-ACYLATED DERIVATIVES HAVING A HIGH MELTING POINT, AND METHODS FOR PREPARING SAME - The oil-in-water cosmetic topical emulsion contains: (1) 95 to 50 wt % of an aqueous phase (P1); and (2) 5 to 50 wt % of a fatty phase (P2), wherein the fatty phase (P2) particularly includes: 0.2 to 60 wt %, specifically 2 to 20 wt %, of at least one N-acylated amino acid derivative of formula (I): R1-C(═O)—NH—CH— (R′06-13-2013
20110313041FOOD SUPPLEMENTS ON THE BASIS OF PANTOTHENIC ACID - The present invention relates to a dietary supplement for the treatment of weakness in metabolic activity containing Pantothenic acid (CoA), its precursors and/or its salts, a process for its production as well as its use. Application areas of the invention are food industry and medicine.12-22-2011
20100317736COMPOSITION OF THE SKIN EXTERNAL APPLICATION OR THE FOOD FOR ACCELERATING PROLINE RECYCLING BY CONTAINING THEANINE - Disclosed herein is a composition for promoting proline recycling, and more particularly, to a composition for external application to skin or cosmetic food comprising theanine as an active ingredient for promoting expression or activity of prolidase, which is an enzyme to promote proline recycling, thereby increasing collagen synthesis and restoring wrinkle.12-16-2010
20130184350Novel NIDDM Regimen - The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone.07-18-2013
20120088834CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND - The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline solid forms.04-12-2012
20120088833MODIFIED AMINO ACID FOR THE INHIBITION OF PLATELET AGGREGATION - A method of inhibiting blood platelet aggregation in a mammal is provided. The method comprises the administration of a platelet aggregation inhibiting amount of a modified amino acid or pharmaceutically acceptable salt thereof.04-12-2012

Patent applications in class RC(=O)N containing (i.e., carboxamide) (R is C or H)